CVS Health Corp. (CVS) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 23/100
- 10Y CAGR
- 10.1%
- Median YoY
- 8.2%
- YoY volatility
- σ 8.5pp· smooth
- Quarters ≥ 20%
- 4 of 40
- Negative quarters
- 0
- Valuation vs own 10Y history
- P/S 0.3x · 10Y median 0.3x · 33rd percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 4 of 40 → 4 of 40 pts
- Steadiness (typical swing 8.5pp) → 18.9 of 25 pts
- Pace (median 8.2% YoY) → 0 of 20 pts
- Latest quarter (7.3% YoY) → 0 of 15 pts
- Score: 23 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 10.1% | 8.2% | 8.5pp | 4 of 40 | 0 |
| EPSEPS | -11.3% | 7.2% | 51.3pp | 12 of 34 | 15 |
| Op cash flowOperating cash flow | 2.2% | 10.4% | 72.3pp | 16 of 34 | 15 |
| EBITDAEBITDA | 2.6% | 0.1% | 28.4pp | 8 of 36 | 18 |
| FCFFree cash flow | 2.4% | 14.3% | 105.9pp | 16 of 34 | 15 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: CVS on the compounders surface · All compounders, ranked